Suppr超能文献

抗抑郁药在阿尔茨海默病中的应用:聚焦米氮平的作用

Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine.

作者信息

Correia Ana Salomé, Vale Nuno

机构信息

OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.

Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.

出版信息

Pharmaceuticals (Basel). 2021 Sep 16;14(9):930. doi: 10.3390/ph14090930.

Abstract

Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also used in obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts mainly by antagonizing the adrenergic α2, and the serotonergic 5-HT2 and 5-HT3 receptors. Neuropsychiatric symptoms, such as depression and agitation, are strongly associated with Alzheimer's disease, reducing the life quality of these patients. Thus, it is crucial to control depression in Alzheimer's patients. For this purpose, drugs such as mirtazapine are important in the control of anxiety, agitation, and other depressive symptoms in these patients. Indeed, despite some contradictory studies, evidence supports the role of mirtazapine in this regard. In this review, we will focus on depression in Alzheimer's disease, highlighting the role of mirtazapine in this context.

摘要

米氮平属于抗抑郁药类别,临床上主要用于治疗重度抑郁症,但也用于强迫症、广泛性焦虑症和睡眠障碍。这种药物主要通过拮抗肾上腺素能α2以及血清素能5-HT2和5-HT3受体发挥作用。神经精神症状,如抑郁和激动,与阿尔茨海默病密切相关,会降低这些患者的生活质量。因此,控制阿尔茨海默病患者的抑郁至关重要。为此,米氮平这类药物对于控制这些患者的焦虑、激动和其他抑郁症状很重要。事实上,尽管有一些相互矛盾的研究,但证据支持米氮平在这方面的作用。在这篇综述中,我们将聚焦于阿尔茨海默病中的抑郁,突出米氮平在这种情况下的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/068f/8467729/86c480137160/pharmaceuticals-14-00930-g001.jpg

相似文献

1
Antidepressants in Alzheimer's Disease: A Focus on the Role of Mirtazapine.
Pharmaceuticals (Basel). 2021 Sep 16;14(9):930. doi: 10.3390/ph14090930.
2
Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
CNS Drugs. 1996 May;5(5):389-402. doi: 10.2165/00023210-199605050-00007.
4
Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.
Biol Psychiatry. 2000 Jul 1;48(1):75-8. doi: 10.1016/s0006-3223(00)00882-9.
5
A risk-benefit assessment of mirtazapine in the treatment of depression.
Drug Saf. 1997 Oct;17(4):251-64. doi: 10.2165/00002018-199717040-00005.
6
Mirtazapine: a review of its use in major depression.
Drugs. 1999 Apr;57(4):607-31. doi: 10.2165/00003495-199957040-00010.

引用本文的文献

1
Mirtazapine revisited: new therapeutic perspectives and formulation advances.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug 23. doi: 10.1007/s00210-025-04525-w.
3
Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition.
Chem Biodivers. 2025 Aug;22(8):e202403401. doi: 10.1002/cbdv.202403401. Epub 2025 Jun 3.
4
Anxiolytic, Antidepressant, and Anticholinesterase Effects of Essential Oil from (G.Mey.) DC.
Biomolecules. 2025 Jan 12;15(1):110. doi: 10.3390/biom15010110.
7
Alzheimer's Disease: Exploring the Landscape of Cognitive Decline.
ACS Chem Neurosci. 2024 Nov 6;15(21):3800-3827. doi: 10.1021/acschemneuro.4c00339. Epub 2024 Oct 11.
8
Addressing depression in older adults with Alzheimer's through cognitive behavioral therapy: systematic review and meta-analysis.
Front Aging Neurosci. 2023 Sep 13;15:1222197. doi: 10.3389/fnagi.2023.1222197. eCollection 2023.
9
Exploring the Role of Drug Repurposing in Bridging the Hypoxia-Depression Connection.
Membranes (Basel). 2023 Sep 17;13(9):800. doi: 10.3390/membranes13090800.
10
Pathogenesis of miR-155 on nonmodifiable and modifiable risk factors in Alzheimer's disease.
Alzheimers Res Ther. 2023 Jul 14;15(1):122. doi: 10.1186/s13195-023-01264-z.

本文引用的文献

2
Amyloid-β Impairs Dendritic Trafficking of Golgi-Like Organelles in the Early Phase Preceding Neurite Atrophy: Rescue by Mirtazapine.
Front Mol Neurosci. 2021 Jun 3;14:661728. doi: 10.3389/fnmol.2021.661728. eCollection 2021.
3
Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.
Pharmaceuticals (Basel). 2021 May 13;14(5):458. doi: 10.3390/ph14050458.
4
Alzheimer disease.
Nat Rev Dis Primers. 2021 May 13;7(1):33. doi: 10.1038/s41572-021-00269-y.
5
Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management.
Front Psychiatry. 2021 Feb 26;12:638651. doi: 10.3389/fpsyt.2021.638651. eCollection 2021.
6
Alzheimer's disease.
Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2.
7
Comprehensive Review on Alzheimer's Disease: Causes and Treatment.
Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789.
9
Depression-an underrecognized target for prevention of dementia in Alzheimer's disease.
Transl Psychiatry. 2020 May 20;10(1):160. doi: 10.1038/s41398-020-0839-1.
10
The neuroscience of depressive disorders: A brief review of the past and some considerations about the future.
Brain Neurosci Adv. 2018 Oct 8;2:2398212818799269. doi: 10.1177/2398212818799269. eCollection 2018 Jan-Dec.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验